From London to Monaco: Health Innovation, Human Stories, and the Future of Consumer Care

Reflections from Crest’s European MedTech Roadshow

Some roadshows are built around markets.

Others are built around people.

Our October healthcare roadshow through London, Milan and Monaco became memorable not simply because of the technologies being presented, but because nearly every conversation eventually returned to something deeply personal: pain, caregiving, travel, family, protection and quality of life.

From a breakfast gathering in London on 7 October, to private lunches in Milan and Monaco on 8 and 9 October, Crest Family Office Forums brought together family office principals, investors and healthcare-focused executives to explore a new generation of healthcare innovations and medical technologies that are quietly reshaping modern healthcare delivery.

The discussions centred around two highly differentiated companies introduced by Dr. Tamir Gedo: TempraMed and Livia.

At first glance, the companies address entirely different challenges. One protects temperature-sensitive medications through patented storage technology. The other offers women a scientifically validated, drug-free wearable device for menstrual pain relief. Yet both shared a common theme that resonated strongly throughout the week: practical healthcare innovation designed to improve everyday life in tangible, human ways.

Our London session was hosted as an intimate breakfast discussion moderated by good friend, and industry expert, Everett Kamin, whose more than twenty-five years of healthcare investment experience brought an invaluable family office perspective to the morning.

Everett has spent decades evaluating healthcare opportunities across both private and institutional environments, including senior leadership roles within prominent family offices. His moderation helped frame the discussions not merely through the lens of technology, but through the questions many families themselves are increasingly asking:

Will this improve lives in a meaningful way?Can the business scale responsibly?Does the management team understand long-term stewardship?And importantly, does the innovation solve a real problem people genuinely face?

Those themes continued throughout the roadshow.

In Milan and Monaco, the forums shifted into more relaxed luncheon settings, allowing guests additional time to engage directly with Dr. Tamir Gedo and Julia Becker, who leads corporate marketing.

One of the things I continue to appreciate about smaller family office gatherings is the ability to move naturally between formal discussion and personal interaction. Conversations become less performative and more honest. Questions become more nuanced. People begin sharing their own experiences, which is exactly what happened throughout the week.

And nowhere was that more evident than with TempraMed.

TempraMed has developed patented, FDA-registered, space-grade insulation technology designed to protect temperature-sensitive medications such as insulin and EpiPens from heat, cold and light exposure during travel and everyday use.

What made the discussions especially powerful was how quickly they became personal for people in the room.

At one point during the roadshow, guests were literally passing my own EpiPen around the table inside one of TempraMed’s protective containers while discussing travel, parenting and medication safety. It created an unexpectedly engaging and almost theatrical moment, not because of a polished presentation slide, but because everyone immediately understood the real-world relevance.

There is something remarkably effective about allowing people to physically experience a technology rather than simply hear about it.

The same was true with Livia.

Livia’s wearable device uses patented SmartWave™ micro-pulse technology to provide women with a drug-free alternative for menstrual pain management. Rather than limiting the conversation to theory, demonstrations allowed guests to experience the device directly on their own forearms, which instantly transformed the room’s level of curiosity and engagement.

What could have easily remained a technical healthcare discussion instead became interactive, experiential and, at times, surprisingly fun.

Watching serious investors, many of whom spend their lives evaluating businesses across multiple sectors, testing the device on one another with genuine fascination created exactly the kind of atmosphere Crest seeks to encourage: informed, relaxed and highly engaged dialogue.

Underlying both companies was a broader discussion led by Dr. Tamir Gedo surrounding a different approach to healthcare investing and venture development.

Dr. Gedo’s background spans life sciences, economics and commercialization strategy, and throughout the week he spoke extensively about the importance of bridging the gap between breakthrough innovation and practical execution. The model presented was intentionally investor-centric, focused on identifying mature startups already generating revenue, approaching cash flow positivity and positioned for scale before introducing broader co-investment participation.

For many family offices, this disciplined approach to company selection and long-term alignment proved just as interesting as the underlying technologies themselves.

What struck me most throughout the roadshow, however, was how emotional healthcare discussions can become once people move beyond spreadsheets and market projections.

For me personally, TempraMed’s story carried particular meaning.

More than a decade ago, I experienced anaphylactic shock for the first time and was rushed to the emergency room. Months later, after a second terrifying episode, I finally learned the unlikely culprit: celery. Since then, I have travelled everywhere with multiple EpiPens, believing they would always be there if needed.

What I did not know until meeting TempraMed was how vulnerable those medications are to temperature exposure during ordinary travel.

When I checked my own EpiPens, the liquid inside had discoloured. None of them would have worked properly in an emergency.

That realization stayed with me throughout the week. You can read more about my personal reflections here.

As we travelled between London, Milan and Monaco introducing TempraMed to family office audiences, there was something quietly meaningful about watching my own EpiPen being safely passed around inside one of their containers while discussing the broader implications for parents, travellers and anyone relying on temperature-sensitive medication.

It reminded me why this work matters.

At Crest, we spend a great deal of time discussing markets, industries and emerging sectors, but the most compelling innovations are often the ones that solve deeply human problems in practical ways.

By the conclusion of our final luncheon in Monaco, the conversations had evolved far beyond healthcare investing alone. Guests were discussing family experiences, travel routines, caregiving, preventative medicine and the growing desire amongst many family offices to support businesses capable of delivering both commercial success and genuine societal value.

And perhaps that was the real takeaway from the week.

The future of healthcare innovation may not belong solely to large institutional systems or pharmaceutical giants. Increasingly, it may also come from agile entrepreneurs and highly focused technologies capable of improving everyday life in ways people can immediately feel, experience and understand for themselves.

Interested in future healthcare and innovation forums? Request an invitation.